JP2016510766A - １型糖尿病の処置及び／又は予防のための方法及び組成物 - Google Patents

１型糖尿病の処置及び／又は予防のための方法及び組成物 Download PDF

Info

Publication number
JP2016510766A
JP2016510766A JP2015561751A JP2015561751A JP2016510766A JP 2016510766 A JP2016510766 A JP 2016510766A JP 2015561751 A JP2015561751 A JP 2015561751A JP 2015561751 A JP2015561751 A JP 2015561751A JP 2016510766 A JP2016510766 A JP 2016510766A
Authority
JP
Japan
Prior art keywords
cells
antigen
cell
progenitor cells
stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015561751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510766A5 (enExample
Inventor
ザグホウアニ ハビブ
ザグホウアニ ハビブ
Original Assignee
ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ
ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ, ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ filed Critical ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ
Publication of JP2016510766A publication Critical patent/JP2016510766A/ja
Publication of JP2016510766A5 publication Critical patent/JP2016510766A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015561751A 2013-03-08 2014-03-10 １型糖尿病の処置及び／又は予防のための方法及び組成物 Pending JP2016510766A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361775115P 2013-03-08 2013-03-08
US61/775,115 2013-03-08
PCT/US2014/022321 WO2014138725A1 (en) 2013-03-08 2014-03-10 Methods and compositions for the treatment and/or prevention of type 1 diabetes

Publications (2)

Publication Number Publication Date
JP2016510766A true JP2016510766A (ja) 2016-04-11
JP2016510766A5 JP2016510766A5 (enExample) 2017-04-06

Family

ID=51492039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015561751A Pending JP2016510766A (ja) 2013-03-08 2014-03-10 １型糖尿病の処置及び／又は予防のための方法及び組成物

Country Status (7)

Country Link
US (2) US11338036B2 (enExample)
EP (1) EP2964750B1 (enExample)
JP (1) JP2016510766A (enExample)
CN (1) CN105358678A (enExample)
AU (1) AU2014225307A1 (enExample)
CA (1) CA2904586A1 (enExample)
WO (1) WO2014138725A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018010937A2 (pt) 2015-12-04 2018-12-04 Novartis Ag composições de anticorpos enxertados com citocina e métodos de uso para imunorregulação
US20200030377A1 (en) * 2016-09-23 2020-01-30 The Curators Of The University Of Missouri Antigen-specific immune modulation
JP2018141728A (ja) * 2017-02-28 2018-09-13 トヨタ自動車株式会社 生活習慣病の診断方法
IL322309A (en) 2017-05-24 2025-09-01 Novartis Ag IL2 antibody grafted proteins and methods of use in cancer treatment
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
CN119236066A (zh) * 2019-05-14 2025-01-03 普瑞文森生物有限公司 用于预防i型糖尿病的方法和组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126374A1 (en) * 2002-04-09 2004-07-01 The Curators Of The University Of Missouri Sustained treatment of type 1 diabetes after expression of predisposition markers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4486188A (en) 1980-08-14 1984-12-04 Applied Medical Devices, Inc. Bone marrow transplant method and apparatus
US4481946A (en) 1980-08-14 1984-11-13 Altshuler John H Bone marrow transplant method and apparatus
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
US7744876B2 (en) 2002-04-09 2010-06-29 The Curators Of The University Of Missouri Methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes
US8603472B2 (en) 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide
US8603471B2 (en) 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions for preventing the onset of type 1 diabetes
WO2005026335A2 (en) 2003-09-15 2005-03-24 Ramot At Tel Aviv University Ltd. Insulin-producing bone marrow derived cells and methods of generating and using same
DK1694354T3 (da) * 2003-11-27 2009-10-26 Develogen Ag Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin
US20120058105A1 (en) * 2008-06-27 2012-03-08 Martin Kean Chong Ng Method of treatment of vascular complications

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126374A1 (en) * 2002-04-09 2004-07-01 The Curators Of The University Of Missouri Sustained treatment of type 1 diabetes after expression of predisposition markers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JEM, vol. 205, no. 1, JPN6017044394, 2008, pages 207 - 218, ISSN: 0003829655 *
PNAS, vol. 104, no. 7, JPN6017044389, 2007, pages 2337 - 2342, ISSN: 0003829654 *

Also Published As

Publication number Publication date
CA2904586A1 (en) 2014-09-12
CN105358678A (zh) 2016-02-24
US11338036B2 (en) 2022-05-24
US20220008535A1 (en) 2022-01-13
WO2014138725A1 (en) 2014-09-12
US20160015811A1 (en) 2016-01-21
EP2964750A4 (en) 2016-08-17
EP2964750B1 (en) 2019-03-06
EP2964750A1 (en) 2016-01-13
AU2014225307A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
JP7561893B2 (ja) 自己免疫関連障害または炎症性障害の治療のための低用量ｉｌ－２の使用
US20220008535A1 (en) Methods and compositions for the treatment and/or prevention of type 1 diabetes
JP6416855B2 (ja) 自己免疫関連障害または炎症性障害の治療のための低用量ｉｌ−２の使用
AU2014337385B2 (en) Chimeric antigen receptor T cell switches and uses thereof
KR20160014584A (ko) 염증 치료용 면역-변형된 입자
US11446314B2 (en) Immunoablative therapies
Shen et al. Systemic delivery of mPEG‐masked trispecific T‐cell nanoengagers in synergy with STING agonists overcomes immunotherapy resistance in TNBC and generates a vaccination effect
US11865168B2 (en) Compositions and methods for treating bacterial infections
US9821035B2 (en) Preparation for preventing or treating type I diabetes
US20240226168A1 (en) Engineered nk cells and uses thereof
WO2022161484A1 (en) Methods of treating chronic active antibody-mediated rejection using btk inhibitors
US20220323506A1 (en) Oligodendrocyte-derived Extracellular Vesicles for Therapy of Multiple Sclerosis
EP3632446B1 (en) Immunoablative therapies
HK40074225A (en) Oligodendrocyte-derived extracellular vesicles for therapy of multiple sclerosis
WO2022143905A1 (zh) 一种治疗糖尿病的药物及其方法
EA043659B1 (ru) Иммуноаблативные виды терапии
US20160361414A1 (en) Methods of Treating and Preventing Minor Histocompatibility Antigen-Mismatched Grafts
Haase Immunology and Immunotherapy of Graft-Versus-Host Disease
HK1186117A (en) Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151007

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180703